The latest biotech news - Labiotech.eu

Home News and Trends Page 51

Latest Posts

Greece Greek flag

News and Trends 19 Dec 2022

Watch: Biotech in Greece

Greece was one of the countries exhibiting at Bio-Europe, held in Leipzig, Germany. Greece isn’t necessarily well known for biotech, but it has good infrastructure, is located at a crossroads between Europe and Africa and the Middle East, and has excellent universities. And its biotech industry is certainly growing. Enterprise Greece spearheaded the biotech presence […]

December 19, 2022 - 1 minutemin - By Jim Cornall

Leipzig Messe Germany

News and Trends 19 Dec 2022

Watch: Atriva Therapeutics at BIO-Europe

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. […]

December 19, 2022 - 1 minutemin - By Jim Cornall

Leipzig Messe Bio-Europe

News and Trends 19 Dec 2022

Watch: Adrenomed tackling huge issue of sepsis

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Its mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead […]

December 19, 2022 - 1 minutemin - By Jim Cornall

bladder cancer

News and Trends 19 Dec 2022

UroGen completes bladder cancer phase 3 trial enrollment

UroGen Pharma Ltd. says its phase 3 ENVISION study of investigational agent UGN-102 (mitomycin) for intravesical solution in development for the treatment of LG-IR-NMIBC is fully enrolled. The study targeted enrollment of 220 patients across 90 sites and, assuming positive findings, UroGen anticipates submitting a New Drug Application (NDA) for UGN-102 in 2024. “Completing enrollment […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

acute myeloid leukaemia leukemia AML

News and Trends 19 Dec 2022

Ordaōs and Yatiri Bio to tackle AML

Ordaōs has announced a joint development agreement to create new therapeutics for two novel targets in acute myeloid leukemia (AML) with Yatiri Bio. Ordaōs is a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, and Yatiri Bio is a biotechnology company that has developed a proprietary platform that links patient proteomic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

M&A Mergers and acquisitions

News and Trends 19 Dec 2022

Prenetics acquires ACT Genomics

Prenetics Global Limited is acquiring a majority stake in ACT Genomics Holdings Company Limited, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the U.K. “With the addition of ACT’s technologies, capabilities and team, Prenetics will be well-positioned to accelerate the utilization of genetic […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT

shutterstock lung cancer

News and Trends 19 Dec 2022

Jacobio’s cancer treatment given breakthrough therapy designations by China CDE

Jacobio Pharma’s in-house KRAS G12C inhibitor JAB-21822 has been granted breakthrough therapy designations in China. The designations are for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation. The designations were granted by the Center for Drug Evaluation (CDE) of the National Medical Products […]

December 19, 2022 - 2 minutesmins - By Jim Cornall

cancer tumour tumor cells

News and Trends 19 Dec 2022

Sanofi and Innate Pharma expand natural killer cell deal

Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

cell therapy

News and Trends 19 Dec 2022

LIfT BioSciences gets a double boost

LIfT BioSciences’ is receiving more investment, and has been accepted into Johnson & Johnson Innovation’s JLABS network. LIfT BioSciences’ lead investor, Starbloom Capital, provided further investment into the company to accelerate LIfT’s R&D plans and progress N-LIfT, the company’s first-to-market anti-cancer innate cell therapy, (neutrophil only leukocyte infusion therapy) into clinical development by Q1 2024, […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

chronic wound

News and Trends 19 Dec 2022

SoftOx receives chronic wound study report

Norwegian company SoftOx Solutions AS says it has received the final report and analysis of its phase 1 study evaluating the safety and tolerability of SoftOx Biofilm Eradicator (SBE-01). SBE-01 is SoftOx’s antimicrobial solution for the treatment of chronic wounds. The study is a first-in-human investigation of the safety, tolerability, and antimicrobial efficacy of single […]

December 19, 2022 - 2 minutesmins - By Jim Cornall

plasmid DNA

News and Trends 19 Dec 2022

Nykode Therapeutics and Richter-Helm BioLogics announce partnership

Nykode Therapeutics ASA has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity […]

December 19, 2022 - 3 minutesmins - By Jim Cornall

university Gothenburg Göteborg

News and Trends 16 Dec 2022

Swedish research center expanding to take on antimicrobial resistance

Research on antibiotic resistance will get a boost when the Center for Antibiotic Resistance Research (CARe) in Gothenburg, Sweden, expands. Bacterial resistance to antibiotics is one of the most serious global health threats. More than a million people die annually as a direct result of infections caused by resistant bacteria. Lack of effective antibiotics jeopardizes […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

ADVERTISEMENT